losartan has been researched along with Cardiomegaly in 128 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist." | 7.78 | Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012) |
| "Mechanical stress can induce cardiac hypertrophy through angiotensin II (AngII) type 1 (AT(1)) receptor independently of AngII, however, the intracellular mechanisms remain largely indeterminate." | 7.76 | Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. ( Ge, J; Gong, H; Li, L; Niu, Y; Sun, A; Wu, J; Zhou, N; Zou, Y, 2010) |
| "The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments." | 7.76 | Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010) |
| "The aim of this study was to provide new insights into the role of angiotensin II and arterial pressure in the regulation of antioxidant enzyme activities in a renovascular model of cardiac hypertrophy." | 7.74 | Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension. ( Balestrasse, KB; Gorzalczany, S; Noriega, GO; Polizio, AH; Taira, C; Tomaro, ML; Yannarelli, GG, 2008) |
| " We employed rats with myocardial infarction (MI) to examine effects of an angiotensin-converting enzyme inhibitor, imidapril, on SR Ca(2+) transport, protein content, and gene expression." | 7.73 | Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. ( Dhalla, NS; Netticadan, T; Ren, B; Saini, HK; Shao, Q; Takeda, N, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 7.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "Hypertension caused by angiotensin II (Ang II) infusion is associated with oxidative stress in the peripheral vasculature and kidney." | 7.72 | Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. ( Davisson, RL; Lazartigues, E; Sharma, RV; Zimmerman, MC, 2004) |
| "The fact that both E and L delayed cardiac hypertrophy/hyperplasia and aortic growth and raised aortic endothelium NOS activity indicates a protective effect on cardiovascular damage due to aging, exerted through inhibition of angiotensin II." | 7.71 | Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. ( Basso, N; González Bosc, LV; Kurnjek, ML; Müller, A; Terragno, NA, 2001) |
| "Cardiac hypertrophy is common in hypertension but its development is influenced by angiotensin II, sodium intake aldosterone, and the time of day blood pressure (BP) is elevated." | 7.71 | Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy. ( Aubert, JF; Brunner, H; Morgan, T, 2001) |
| "To assess the possible contribution of the circulatory and cardiac renin-angiotensin system (RAS) to the cardiac hypertrophy induced by a beta-agonist, the present study evaluated the effects of isoproterenol, alone or combined with an angiotensin I-converting enzyme inhibitor or AT(1) receptor blocker, on plasma and LV renin activity, ANG I, and ANG II, as well as left ventricular (LV) and right ventricular (RV) weight." | 7.71 | Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. ( Leenen, FH; White, R; Yuan, B, 2001) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 7.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| "This study was designed to investigate the effects of chronic inhibition of NO synthesis as well as chronic angiotensin receptor blockade with losartan in the development of hypertension, on mesenteric arterial bed reactivity as well as on the development of cardiac and kidney hypertrophy in deoxycorticosterone-salt (DOCA) hypertension." | 7.70 | Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. ( Cardinal, R; de Champlain, J; K-Laflamme, A; Oster, L, 1998) |
| " The aim of the present study was to test whether calcineurin is involved in the signal transduction of angiotensin II (AngII)-induced cardiac myocyte hypertrophy and fibroblast hyperplasia." | 7.70 | Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats. ( Fu, M; Liu, N; Pang, Y; Su, J; Tang, C; Xu, S; Zhang, J, 1999) |
| "We assessed the role of angiotensin (Ang) II type 1 receptor (AT1) and endothelin type A and B (ETA & ETB) receptor in cardiovascular hypertrophy associated with angiotensin II-induced hypertension (200 ng/kg." | 7.70 | [Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan]. ( Belabbas, H; Herizi, A; Jover, B; Mimran, A, 2000) |
| "In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors." | 7.69 | Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995) |
| "To investigate the contribution of a cardiac renin-angiotensin system to cardiac hypertrophy due to volume overload, the effects of losartan, a non-peptide angiotensin (Ang) II type 1 (AT1) receptor antagonist on left ventricular hypertrophy (LVH) was studied." | 7.69 | Effects of losartan, an angiotensin II antagonist, on the development of cardiac hypertrophy due to volume overload. ( Ishiye, M; Nakashima, M; Uematsu, T; Umemura, K, 1995) |
| "The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats." | 7.69 | Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994) |
| "To investigate the role of angiotensin II (Ang II) in cardiovascular hypertrophy in the Goldblatt one-kidney, one clip (1-K, 1C) renal hypertensive rat." | 7.69 | Cardiovascular hypertrophy in one-kidney, one clip renal hypertensive rats: a role for angiotensin II? ( Bertram, JF; Black, MJ; Bobik, A; O'Sullivan, JB, 1994) |
| "In the present study, we evaluated the effects of blockade of the RAS by the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor blocker losartan on left ventricular (LV) and right ventricular mass and LV dilation in relation to changes in central hemodynamics during the maintenance of minoxidil and aortocaval shunt-induced cardiac hypertrophy." | 7.69 | Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. ( Leenen, FH; Ruzicka, M; Yuan, B, 1994) |
| "The purpose of this study was to evaluate the role of angiotensin II (AII) in fructose-treated rats by assessing the effects of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity." | 7.69 | Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. ( Iyer, SN; Katovich, MJ, 1996) |
| " Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group." | 7.69 | Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996) |
| " To evaluate the possible involvement of the RAS in the development of minoxidil-induced cardiac hypertrophy, we assessed in normotensive rats minoxidil-induced changes in cardiac and plasma renin activity (PRA) and the potential of chronic treatment with the angiotensin-converting enzyme (ACE) inhibitor enalapril and the nonpeptide angiotensin II receptor blocker losartan to prevent minoxidil-induced cardiac hypertrophy." | 7.68 | Renin-angiotensin system and minoxidil-induced cardiac hypertrophy in rats. ( Leenen, FH; Ruzicka, M, 1993) |
| "To evaluate the role of the renin-angiotensin system in volume overload-induced cardiac hypertrophy, we assessed: 1) the time course of changes in cardiac hemodynamics, cardiac anatomy, and plasma and cardiac renin activity in response to volume overload induced by two sizes of abdominal aortocaval shunt and 2) the effects of chronic treatment with an angiotensin converting enzyme inhibitor (ACEI) versus an angiotensin II receptor blocker on hemodynamics and cardiac hypertrophy." | 7.68 | The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. ( Harmsen, E; Leenen, FH; Ruzicka, M; Yuan, B, 1993) |
| "Persistent cardiac hypertrophy eventually leads to deterioration of heart function and changes to normal morphology." | 5.51 | Interleukin enhancement binding factor 3 inhibits cardiac hypertrophy by targeting asymmetric dimethylarginine-nitric oxide. ( Ge, LJ; Peng, XD; Sun, JC; Tan, X; Wang, WZ; Yang, RH, 2019) |
| "Treatment with Losartan (10 mg/kg per day) lowered blood pressure markedly." | 5.28 | Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. ( Fukuchi, S; Hashimoto, S; Mizuno, K; Niimura, S; Ohtsuki, M; Sanada, H; Tani, M; Watanabe, H, 1992) |
| "Male cardiac-specific BACH1 knockout mice or cardiac-specific BACH1 transgenic (BACH1-Tg) mice and their respective wild-type littermates developed cardiac hypertrophy induced by angiotensin II (Ang II) or transverse aortic constriction (TAC)." | 4.31 | Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. ( Chen, L; Ge, F; Guo, J; He, Y; Hu, K; Jia, M; Jiang, L; Jin, J; Li, L; Li, Q; Lv, X; Ma, S; Meng, D; Osto, E; Wang, X; Wei, X; Wu, H; Wu, J; Yang, Z; Zhang, J; Zhi, X, 2023) |
| " Cardiac hypertrophy of mice was elicited by isoproterenol (ISO) infusion (40 mg/kg per day for 14 days)." | 3.85 | Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy. ( Chen, XH; Ding, YY; Li, JM; Liu, Y; Lu, XL; Pan, XC; Tong, YF; Wang, Y; Zhang, HG, 2017) |
| " β-AR overstimulation with associated cardiac hypertrophy and increased vasoconstrictor response to phenylephrine in aorta were modeled in rats by 7-day isoproterenol treatment." | 3.83 | Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue. ( Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA, 2016) |
| "We used myocytes from Wistar, SHR, losartan-treated SHR (Los-SHR), and Angiotensin II (Ang II)-induced cardiac hypertrophy." | 3.80 | Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system. ( Aiello, EA; Caldiz, CI; Ciancio, MC; De Giusti, VC; Orlowski, A, 2014) |
| "The chronic nandrolone treatment impairs the exercise-induced cardioprotection against ischaemia/reperfusion injury by activating the cardiac renin-angiotensin-aldosterone system and downregulating KATP channel expression." | 3.80 | AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion. ( Campos de Carvalho, AC; Ferraz, EB; Marques-Neto, SR; Nascimento, JH; Njaine, B; Rodrigues, DC; Rondinelli, E, 2014) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| "Forty-four adult male Sprague-Dawley rats were divided into four groups: control group (saline), losartan group (10 mg/kg), thyrotoxicosis group (0." | 3.79 | Ang II receptor expression and effect of Ang II receptor blockade in thyrotoxic rat myocardium. ( Cao, YX; Ma, AQ; Wang, WF; Wang, XH, 2013) |
| " We here examined the effects of QL on the development of cardiac hypertrophy through comparing those of losartan in C57BL/6 mice underlying transverse aorta constriction for 4 weeks." | 3.78 | Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. ( Ge, J; Gong, H; Jia, Z; Li, L; Li, Y; Liang, Y; Lin, L; Wei, J; Wu, J; Wu, Y; Ye, Y; Zhou, J; Zhou, N; Zou, Y, 2012) |
| " Treatment with losartan significantly attenuated TAC-induced cardiac hypertrophy, in parallel with decreased expression of RANKL, TNF-α, IL-1α, and IL-1β." | 3.78 | Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. ( Abel, ED; Ahn, J; Kim, HS; Kim, J; Lee, SH; Lee, WS; Min, JK; Ock, S; Oh, GT; Oh, JG; Park, H; Park, WJ; Rho, J; Son, JW; Yang, DK, 2012) |
| "67 Mb heterozygous deletion including the Eln gene, presented with a generalized arteriopathy, hypertension, and cardiac hypertrophy, associated with elevated angiotensin II (angII), oxidative stress parameters, and Ncf1 expression." | 3.78 | Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome. ( Bustelo, XR; Campuzano, V; Coustets, M; Francke, U; Menacho-Márquez, M; Nevado, J; Pérez-Jurado, LA; Sánchez-Rodríguez, C; Segura-Puimedon, M; Terrado, V, 2012) |
| "This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist." | 3.78 | Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012) |
| "Mechanical stress can induce cardiac hypertrophy through angiotensin II (AngII) type 1 (AT(1)) receptor independently of AngII, however, the intracellular mechanisms remain largely indeterminate." | 3.76 | Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. ( Ge, J; Gong, H; Li, L; Niu, Y; Sun, A; Wu, J; Zhou, N; Zou, Y, 2010) |
| "Baseline and third year ECG LVH and left atrial systolic diameter were examined in 663 patients in the Losartan Intervention For Endpoint reduction in hypertension echocardiographic substudy who were in sinus rhythm at baseline and had no history of atrial fibrillation." | 3.76 | Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K, 2010) |
| "The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments." | 3.76 | Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010) |
| " Here we compared the effects of five commonly used ARBs (Candesartan, Olmesartan, Losartan, Telmisartan and Valsartan) on pressure overload-induced cardiac hypertrophy in mice model." | 3.76 | Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. ( Ge, J; Gong, H; Komuro, I; Li, L; Lin, L; Wu, J; Zhou, N; Zou, Y, 2010) |
| " Thus, the aim of this study was to compare the effects of losartan, angiotensin II type-1 receptor blocker, on systolic (SBP), diastolic (DBP), and mean (MBP) blood pressure, pulse pressure (PP) and heart rate as well as regional haemodynamics, cardiac hypertrophy and biochemical parameters in adult (L(9): 9-month-old) and aged (L(18): 18-month-old) spontaneously hypertensive rats (SHRs)." | 3.75 | Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. ( Grujić-Milanović, J; Ivanov, M; Jovović, D; Mihailović-Stanojević, N; Miloradović, Z, 2009) |
| "Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8." | 3.74 | Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007) |
| "The aim of this study was to provide new insights into the role of angiotensin II and arterial pressure in the regulation of antioxidant enzyme activities in a renovascular model of cardiac hypertrophy." | 3.74 | Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension. ( Balestrasse, KB; Gorzalczany, S; Noriega, GO; Polizio, AH; Taira, C; Tomaro, ML; Yannarelli, GG, 2008) |
| " We employed rats with myocardial infarction (MI) to examine effects of an angiotensin-converting enzyme inhibitor, imidapril, on SR Ca(2+) transport, protein content, and gene expression." | 3.73 | Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. ( Dhalla, NS; Netticadan, T; Ren, B; Saini, HK; Shao, Q; Takeda, N, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 3.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "The present study evaluates the participation of oxidative stress, tissue angiotensin II (Ang II) and endothelin (ET) in the effects of losartan on blood pressure (BP), ventricular hypertrophy and renal injury in spontaneously hypertensive rats (SHRs), and explores how these effects are modified when spontaneous hypertension is transformed in a low-renin model by the administration of deoxycorticosterone acetate (DOCA)." | 3.72 | Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats. ( Chamorro, V; Duarte, J; O'Valle, F; Osuna, A; Sainz, J; Vargas, F; Wangensteen, R, 2004) |
| " The aim of this study was to investigate the role of angiotensin II (Ang II), a major inducer of cardiac hypertrophy, in the reexpression of T-type channel in left ventricular hypertrophied myocytes." | 3.72 | Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels. ( Capuano, V; Coulombe, A; Deroubaix, E; Ferron, L; Renaud, JF; Ruchon, Y, 2003) |
| "Hypertension caused by angiotensin II (Ang II) infusion is associated with oxidative stress in the peripheral vasculature and kidney." | 3.72 | Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. ( Davisson, RL; Lazartigues, E; Sharma, RV; Zimmerman, MC, 2004) |
| "The fact that both E and L delayed cardiac hypertrophy/hyperplasia and aortic growth and raised aortic endothelium NOS activity indicates a protective effect on cardiovascular damage due to aging, exerted through inhibition of angiotensin II." | 3.71 | Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. ( Basso, N; González Bosc, LV; Kurnjek, ML; Müller, A; Terragno, NA, 2001) |
| "Cardiac hypertrophy is common in hypertension but its development is influenced by angiotensin II, sodium intake aldosterone, and the time of day blood pressure (BP) is elevated." | 3.71 | Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy. ( Aubert, JF; Brunner, H; Morgan, T, 2001) |
| "To assess the possible contribution of the circulatory and cardiac renin-angiotensin system (RAS) to the cardiac hypertrophy induced by a beta-agonist, the present study evaluated the effects of isoproterenol, alone or combined with an angiotensin I-converting enzyme inhibitor or AT(1) receptor blocker, on plasma and LV renin activity, ANG I, and ANG II, as well as left ventricular (LV) and right ventricular (RV) weight." | 3.71 | Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. ( Leenen, FH; White, R; Yuan, B, 2001) |
| " The effect of the angiotensin II type 1 receptor antagonist, losartan (10 mg x kg(-1) x d(-1))on aldosterone-induced cardiac hypertrophy was also studied." | 3.71 | Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. ( Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T, 2002) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 3.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| "The three treatments regressed cardiac hypertrophy and normalized sodium/hydrogen ion exchange exchange activity in SHR, and losartan was the most effective treatment for reversing cardiac hypertrophy, despite producing effects on blood pressure and sodium/hydrogen exchange activity similar to that of other antihypertensive drugs." | 3.71 | Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats. ( Alvarez, BV; Cingolani, HE; De Hurtado, MC; Ennis, IL, 2002) |
| "This study was designed to investigate the effects of chronic inhibition of NO synthesis as well as chronic angiotensin receptor blockade with losartan in the development of hypertension, on mesenteric arterial bed reactivity as well as on the development of cardiac and kidney hypertrophy in deoxycorticosterone-salt (DOCA) hypertension." | 3.70 | Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. ( Cardinal, R; de Champlain, J; K-Laflamme, A; Oster, L, 1998) |
| " The aim of the present study was to test whether calcineurin is involved in the signal transduction of angiotensin II (AngII)-induced cardiac myocyte hypertrophy and fibroblast hyperplasia." | 3.70 | Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats. ( Fu, M; Liu, N; Pang, Y; Su, J; Tang, C; Xu, S; Zhang, J, 1999) |
| "We assessed the role of angiotensin (Ang) II type 1 receptor (AT1) and endothelin type A and B (ETA & ETB) receptor in cardiovascular hypertrophy associated with angiotensin II-induced hypertension (200 ng/kg." | 3.70 | [Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan]. ( Belabbas, H; Herizi, A; Jover, B; Mimran, A, 2000) |
| "In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors." | 3.69 | Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995) |
| "To investigate the contribution of a cardiac renin-angiotensin system to cardiac hypertrophy due to volume overload, the effects of losartan, a non-peptide angiotensin (Ang) II type 1 (AT1) receptor antagonist on left ventricular hypertrophy (LVH) was studied." | 3.69 | Effects of losartan, an angiotensin II antagonist, on the development of cardiac hypertrophy due to volume overload. ( Ishiye, M; Nakashima, M; Uematsu, T; Umemura, K, 1995) |
| "The role of angiotensin II via the angiotensin type 1 (AT1) receptor in the development of volume overload cardiac hypertrophy was investigated in adult male Wistar rats with aortic insufficiency." | 3.69 | Angiotensin AT1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin. ( Ishiye, M; Nakashima, M; Uematsu, T; Umemura, K, 1995) |
| "The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats." | 3.69 | Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994) |
| "To investigate the role of angiotensin II (Ang II) in cardiovascular hypertrophy in the Goldblatt one-kidney, one clip (1-K, 1C) renal hypertensive rat." | 3.69 | Cardiovascular hypertrophy in one-kidney, one clip renal hypertensive rats: a role for angiotensin II? ( Bertram, JF; Black, MJ; Bobik, A; O'Sullivan, JB, 1994) |
| "Primary cultures of neonatal cardiac myocytes were used to determine the identity of second messengers that are involved in angiotensin II (ANG II) receptor-mediated effects on cardiac hypertrophy and the type of ANG II receptor that is involved in ANG II-induced cell growth." | 3.69 | Hypertrophic growth of cultured neonatal rat heart cells mediated by type 1 angiotensin II receptor. ( Haneda, T; Miyata, S, 1994) |
| "In the present study, we evaluated the effects of blockade of the RAS by the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor blocker losartan on left ventricular (LV) and right ventricular mass and LV dilation in relation to changes in central hemodynamics during the maintenance of minoxidil and aortocaval shunt-induced cardiac hypertrophy." | 3.69 | Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. ( Leenen, FH; Ruzicka, M; Yuan, B, 1994) |
| "The blood pressure was decreased after chronic treatment with enalapril, MK-954, and hydralazine in deoxycorticosterone acetate (DOCA)-salt-induced malignant hypertension of spontaneously hypertensive rats (SHR); however, ventricular weight and plasma brain natriuretic peptide (BNP) concentration were decreased after enalapril and MK-954 but not after hydralazine." | 3.69 | Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension. ( Fukui, T; Horio, T; Kohno, M; Kurihara, N; Takeda, T; Yasunari, K; Yokokawa, K; Yoshiyama, M, 1994) |
| "The role of angiotensin II via the angiotensin type 1 or type 2 receptor in the development of cardiac hypertrophy was determined in adult male Sprague-Dawley rats subjected to coarctation of the abdominal aorta." | 3.69 | Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. ( Everett, AD; Fisher, A; Gomez, RA; Tufro-McReddie, A, 1994) |
| "We studied the mechanisms responsible for vascular and cardiac hypertrophy in hypertension (pressure load and humoral and genetic factors) in two experimental approaches: (1) We carried out a cosegregation analysis to correlate cardiac and vascular hypertrophy with subphenotypes of blood pressure in an F2 generation of a cross between stroke-prone spontaneously hypertensive rats (SHRSP) and normotensive Wistar-Kyoto rats; (2) we treated 8-week-old SHRSP with perindopril, an angiotensin-converting enzyme inhibitor; losartan, an angiotensin type 1 receptor antagonist; or perindopril combined with a nitric oxide synthase inhibitor to investigate the relative contributions of blood pressure and angiotensin II to the pathogenesis of cardiac hypertrophy and vascular smooth muscle polyploidy." | 3.69 | Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension. ( Anderson, NH; Bohr, DF; Devlin, AM; Dominiczak, AF; Lee, WK; Reid, JL, 1996) |
| "The purpose of this study was to evaluate the role of angiotensin II (AII) in fructose-treated rats by assessing the effects of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity." | 3.69 | Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. ( Iyer, SN; Katovich, MJ, 1996) |
| "To determine the role of angiotensin II-receptor blockade on cardiovascular remodeling in a pressure-overload model of cardiac hypertrophy, a subdiaphragmatic aortic band was placed in adult male Sprague-Dawley rats." | 3.69 | Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats. ( Anderson, PG; Berecek, KH; Bishop, SP; Regan, CP, 1997) |
| "To examine the role played by angiotensin II (AII) in the development of prehypertensive vascular hypertrophy in the spontaneously hypertensive rat (SHR) and to determine whether normalization of prehypertensive vascular hypertrophy attenuates the development of hypertension." | 3.69 | Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats. ( Black, MJ; Bobik, A; Kanellakis, P, 1997) |
| " Both of the losartan-treated groups presented an apparently reduced cardiac hypertrophy but it was only clear in the low-sodium diet group." | 3.69 | Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system. ( Bonhomme, MC; Diebold, S; Garcia, R, 1996) |
| " To evaluate the possible involvement of the RAS in the development of minoxidil-induced cardiac hypertrophy, we assessed in normotensive rats minoxidil-induced changes in cardiac and plasma renin activity (PRA) and the potential of chronic treatment with the angiotensin-converting enzyme (ACE) inhibitor enalapril and the nonpeptide angiotensin II receptor blocker losartan to prevent minoxidil-induced cardiac hypertrophy." | 3.68 | Renin-angiotensin system and minoxidil-induced cardiac hypertrophy in rats. ( Leenen, FH; Ruzicka, M, 1993) |
| "To elucidate the cellular mechanism by which angiotensin II (ANG II) induces cardiac hypertrophy, we investigated the possible autocrine/paracrine role of endogenous endothelin-1 (ET-1) in ANG II-induced hypertrophy of neonatal rat cardiomyocytes by use of synthetic ET-1 receptor antagonist and antisense oligonucleotides to preproET-1 (ppET-1) mRNA." | 3.68 | Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. ( Adachi, S; Hirata, Y; Hiroe, M; Ito, H; Koike, A; Murumo, F; Nogami, A; Tanaka, M; Tsujino, M, 1993) |
| "To evaluate the role of the renin-angiotensin system in volume overload-induced cardiac hypertrophy, we assessed: 1) the time course of changes in cardiac hemodynamics, cardiac anatomy, and plasma and cardiac renin activity in response to volume overload induced by two sizes of abdominal aortocaval shunt and 2) the effects of chronic treatment with an angiotensin converting enzyme inhibitor (ACEI) versus an angiotensin II receptor blocker on hemodynamics and cardiac hypertrophy." | 3.68 | The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. ( Harmsen, E; Leenen, FH; Ruzicka, M; Yuan, B, 1993) |
| " The angiotensin II type 1 receptor antagonist, losartan, prevented the development of hypertension in spontaneously hypertensive rats (SHR)." | 3.68 | Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers. ( Bobik, A; Dilley, RJ; Oddie, CJ, 1992) |
| "TAC-induced cardiac hypertrophy was observed at 14 days after the operation, which was partially reversed by losartan, but not by PD123319." | 1.62 | Angiotensin II Increases HMGB1 Expression in the Myocardium Through AT1 and AT2 Receptors When Under Pressure Overload. ( Ge, J; Jiang, H; Su, Y; Wang, J; Wu, J; Yu, Y; Zhang, B; Zhang, L; Zou, Y, 2021) |
| "Persistent cardiac hypertrophy eventually leads to deterioration of heart function and changes to normal morphology." | 1.51 | Interleukin enhancement binding factor 3 inhibits cardiac hypertrophy by targeting asymmetric dimethylarginine-nitric oxide. ( Ge, LJ; Peng, XD; Sun, JC; Tan, X; Wang, WZ; Yang, RH, 2019) |
| "Losartan treatment had no impact on growth or kidney development." | 1.43 | Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction. ( Béland-Bonenfant, S; Bertagnolli, M; Cloutier, A; Dios, A; Gascon, G; Lukaszewski, MA; Nuyt, AM; Paradis, P; Schiffrin, EL; Sutherland, M, 2016) |
| "The elevated RBP4 in cardiac hypertrophy may have pathophysiological consequences because RBP4 increased cell size, enhanced protein synthesis, and elevated the expression of hypertrophic markers including Anp, Bnp, and Myh7 in primary cardiomyocytes." | 1.43 | Retinol-Binding Protein 4 Induces Cardiomyocyte Hypertrophy by Activating TLR4/MyD88 Pathway. ( Bao, JZ; Cao, Y; Gao, W; Liu, ZX; Lu, X; Wang, H; Wang, LS; Yang, Q; Zhang, L, 2016) |
| "Losartan treatment completely prevented post-MI cardiac hypertrophy." | 1.42 | Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats. ( Forsten, H; Harjula, A; Immonen, K; Kankuri, E; Kosonen, R; Laine, M; Lakkisto, P; Palojoki, E; Segersvärd, H; Tikkanen, I, 2015) |
| "Treatment with losartan used, the selective antagonist of angiotensin II type I receptor could improve the cardiac function of TAC rats." | 1.42 | [Preliminary Study of Necroptosis in Cardiac Hypertrophy Induced by Pressure Overload]. ( Fu, H; Liu, X; Lu, L; Qin, Y; Tang, X; Wu, W; Zhao, M, 2015) |
| "AMP-kinase (AMPK) activation reduces cardiac hypertrophy, although underlying molecular mechanisms remain unclear." | 1.40 | Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. ( Barreto-Torres, G; Hernández, JS; Javadov, S; Khuchua, Z; Kuznetsov, AV, 2014) |
| "Losartan treatment significantly decreased MAP, left ventricle hypertrophy (LVH), fibrosis, and increased cardiac ACE2 and Mas expression." | 1.40 | Alteration of cardiac ACE2/Mas expression and cardiac remodelling in rats with aortic constriction. ( Li, B; Morgan, T; Wang, B; Wu, J; Zhang, J; Zhang, Y, 2014) |
| "Heart hypertrophy was induced by abdominal aorta CoA (coarctation)." | 1.39 | Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts. ( Almeida, JF; Alves, GM; Castro, CH; Colugnati, DB; Ferreira, AJ; Macedo, LM; Mendes, EP; Porto, JE; Santos, RA; Sobrinho, DB; Souza, ÁP; Vêncio, EF, 2013) |
| " We investigated the changes of ceramide lipid components in hypertrophied immature rabbit hearts after chronic administration of the AT1 -receptor blocker, losartan." | 1.39 | Modulation of C16:0-ceramide in hypertrophied immature hearts by losartan. ( Itoi, T; Oka, T; Terada, N, 2013) |
| "Cardiac hypertrophy was increased 10% by using ND and 17% by ND plus training (P < 0." | 1.37 | Anabolic steroid associated to physical training induces deleterious cardiac effects. ( Barretti, D; Da Silva, ND; de Oliveira, EM; Do Carmo, EC; Fernandes, T; Irigoyen, MC; Koike, D; Mattos, KC; Melo, SF; Rosa, KT; Wichi, RB, 2011) |
| "Losartan was administered (20 mg/kg/day) in drinking water by gavage for 5 weeks." | 1.35 | Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats. ( Cebova, M; Koprdova, R; Kristek, F, 2009) |
| "RV hypertrophy was also prevented, but LV hypertrophy only partially, and kidney hypertrophy not at all." | 1.35 | Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. ( Leenen, FH; Liang, B, 2008) |
| "Cardiac hypertrophy was induced by abdominal aortic stenosis (AAS) in Sprague-Dawley rats." | 1.33 | Role of myofibrillogenesis regulator-1 in myocardial hypertrophy. ( Li, T; Liu, X; Sun, S; Wang, Y; Xu, F, 2006) |
| "Although cardiac hypertrophy in hypertension has been well recognized, the molecular mechanisms for the development of hypertrophy are still largely unknown." | 1.33 | Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. ( Chen, GQ; Chen, WL; Fang, NY; Jin, X; Liu, ZG; Shi, JZ; Wang, LS; Xia, L; Zhang, L; Zheng, Y, 2006) |
| "Losartan normalized blood pressure, cardiac hypertrophy, albuminuria, inflammatory response and morphological changes in mREN2 rats, both in the presence and absence of cyclooxygenase inhibitors." | 1.32 | Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). ( Cheng, ZJ; Finckenberg, P; Louhelainen, M; Merasto, S; Mervaala, EM; Tikkanen, I; Vapaatalo, H, 2003) |
| "To determine whether AII can induce cardiac hypertrophy directly via myocardial AT1R in the absence of vascular changes, transgenic mice overexpressing the human AT1R under the control of the mouse alpha-myosin heavy chain promoter were generated." | 1.31 | Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. ( Dali-Youcef, N; Nemer, M; Paradis, FW; Paradis, P; Thibault, G, 2000) |
| "Co-treatment with losartan prevented all changes." | 1.31 | Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition. ( Boer, P; Braam, B; Gröne, H; Hohbach, J; Joles, JA; Koomans, HA; Verhagen, AM, 2000) |
| " Losartan improved the shifted circadian BP rhythm towards the active phase in a dose-dependent manner, whereas the improvement caused by 1 and 3 mg/day of benazepril was less effective than the same dosage of losartan." | 1.31 | Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP. ( Hayasaki-Kajiwara, Y; Iwasaki, T; Nakajima, M; Naya, N; Shimamura, T, 2002) |
| "Treatment with losartan, an angiotensin II AT(1) receptor antagonist, decreased BP in two-renin gene mice but not in one-renin gene mice." | 1.31 | Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. ( Brunner, HR; Burnier, M; Clément, S; Gabbiani, G; Hummler, E; Nussberger, J; Wang, Q, 2002) |
| "Vascular and cardiac hypertrophy were significantly attenuated with losartan or perindopril, but were unchanged with other treatments." | 1.30 | Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. ( Anderson, NH; Devlin, AM; Dominiczak, AF; Graham, D; Hamilton, CA; Morton, JJ; Reid, JL; Schork, NJ, 1999) |
| "Development of cardiac hypertrophy in ACF seemed independent of angiotensin II." | 1.30 | Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats. ( Friberg, P; Isgaard, J; Wåhlander, H; Wickman, A, 1999) |
| "Regression of cardiac hypertrophy was accompanied by a 50% to 300% increase in DNA fragmentation and a >20% reduction in DNA synthesis, resulting in a >20% reduction in cardiac DNA content after 4 weeks." | 1.30 | Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. ( Dam, TV; deBlois, D; Hamet, P; Moreau, P; Tea, BS, 1999) |
| "Losartan and enalapril treatments completely inhibited the increase of systolic blood pressure occurring with ageing in SHR." | 1.30 | Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. ( Kähönen, M; Kalliovalkama, J; Magga, J; Pörsti, I; Romppanen, H; Ruskoaho, H; Tolvanen, JP; Vuolteenaho, O, 1999) |
| "Losartan treatment initiated 3 weeks after aortic banding and continued for 3 more weeks resulted in a slight but significant reduction in the extent of cardiac hypertrophy (45." | 1.29 | Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal. ( Mohabir, R; Strosberg, AM; Young, SD, 1994) |
| "Hypertensive cardiac hypertrophy is associated with the accumulation of collagen in the myocardial interstitium." | 1.29 | Altered signal transduction system in hypertrophied myocardium: angiotensin II stimulates collagen synthesis in hypertrophied hearts. ( Kawaguchi, H; Kitabatake, A, 1996) |
| "Treatment with Losartan (10 mg/kg per day) lowered blood pressure markedly." | 1.28 | Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. ( Fukuchi, S; Hashimoto, S; Mizuno, K; Niimura, S; Ohtsuki, M; Sanada, H; Tani, M; Watanabe, H, 1992) |
| "Captopril or losartan treatment decreased MAP and returned LVEDP to sham-operated control values." | 1.28 | Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. ( Garcia, R; Qing, G, 1992) |
| "In this animal model, the cardiac hypertrophy appeared to be independent of cardiac afterload, because normalization of blood pressure with hydralazine did not prevent the AII-induced hypertrophy." | 1.28 | Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. ( Baker, KM; Dostal, DE, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (33.59) | 18.2507 |
| 2000's | 44 (34.38) | 29.6817 |
| 2010's | 37 (28.91) | 24.3611 |
| 2020's | 4 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Castoldi, G | 2 |
| Carletti, R | 2 |
| Ippolito, S | 1 |
| Stella, A | 2 |
| Zerbini, G | 2 |
| Pelucchi, S | 1 |
| Zatti, G | 1 |
| di Gioia, CRT | 2 |
| Wei, X | 1 |
| Jin, J | 1 |
| Wu, J | 6 |
| He, Y | 1 |
| Guo, J | 1 |
| Yang, Z | 1 |
| Chen, L | 1 |
| Hu, K | 1 |
| Li, L | 4 |
| Jia, M | 1 |
| Li, Q | 1 |
| Lv, X | 1 |
| Ge, F | 1 |
| Ma, S | 1 |
| Wu, H | 1 |
| Zhi, X | 1 |
| Wang, X | 1 |
| Jiang, L | 1 |
| Osto, E | 1 |
| Zhang, J | 3 |
| Meng, D | 1 |
| Yang, RH | 1 |
| Tan, X | 1 |
| Ge, LJ | 1 |
| Sun, JC | 1 |
| Peng, XD | 1 |
| Wang, WZ | 1 |
| Zhang, L | 3 |
| Zhang, B | 1 |
| Yu, Y | 1 |
| Wang, J | 1 |
| Su, Y | 1 |
| Jiang, H | 1 |
| Zou, Y | 4 |
| Ge, J | 4 |
| Tong, YF | 1 |
| Wang, Y | 2 |
| Ding, YY | 1 |
| Li, JM | 1 |
| Pan, XC | 1 |
| Lu, XL | 1 |
| Chen, XH | 1 |
| Liu, Y | 2 |
| Zhang, HG | 1 |
| Takano, APC | 1 |
| Senger, N | 1 |
| Munhoz, CD | 1 |
| Barreto-Chaves, MLM | 1 |
| Roma, F | 1 |
| Manzoni, G | 1 |
| Perseghin, G | 1 |
| Segersvärd, H | 1 |
| Lakkisto, P | 1 |
| Forsten, H | 1 |
| Immonen, K | 1 |
| Kosonen, R | 1 |
| Palojoki, E | 1 |
| Kankuri, E | 1 |
| Harjula, A | 1 |
| Laine, M | 1 |
| Tikkanen, I | 2 |
| Souza, ÁP | 1 |
| Sobrinho, DB | 1 |
| Almeida, JF | 1 |
| Alves, GM | 1 |
| Macedo, LM | 1 |
| Porto, JE | 1 |
| Vêncio, EF | 1 |
| Colugnati, DB | 1 |
| Santos, RA | 1 |
| Ferreira, AJ | 1 |
| Mendes, EP | 1 |
| Castro, CH | 1 |
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Wang, XH | 1 |
| Wang, WF | 1 |
| Cao, YX | 1 |
| Ma, AQ | 1 |
| Orlowski, A | 1 |
| Ciancio, MC | 1 |
| Caldiz, CI | 1 |
| De Giusti, VC | 1 |
| Aiello, EA | 1 |
| Marques-Neto, SR | 1 |
| Ferraz, EB | 1 |
| Rodrigues, DC | 1 |
| Njaine, B | 1 |
| Rondinelli, E | 1 |
| Campos de Carvalho, AC | 1 |
| Nascimento, JH | 1 |
| Kang, YM | 1 |
| Zhang, DM | 1 |
| Yu, XJ | 1 |
| Yang, Q | 2 |
| Qi, J | 1 |
| Su, Q | 1 |
| Suo, YP | 1 |
| Yue, LY | 1 |
| Zhu, GQ | 1 |
| Qin, DN | 1 |
| Hernández, JS | 1 |
| Barreto-Torres, G | 1 |
| Kuznetsov, AV | 1 |
| Khuchua, Z | 1 |
| Javadov, S | 1 |
| Silva, PA | 1 |
| Monnerat-Cahli, G | 1 |
| Pereira-Acácio, A | 1 |
| Luzardo, R | 1 |
| Sampaio, LS | 1 |
| Luna-Leite, MA | 1 |
| Lara, LS | 1 |
| Einicker-Lamas, M | 1 |
| Panizzutti, R | 1 |
| Madeira, C | 1 |
| Vieira-Filho, LD | 1 |
| Castro-Chaves, C | 1 |
| Ribeiro, VS | 1 |
| Paixão, AD | 1 |
| Medei, E | 1 |
| Vieyra, A | 1 |
| Katayama, IA | 2 |
| Pereira, RC | 1 |
| Dopona, EP | 1 |
| Shimizu, MH | 1 |
| Furukawa, LN | 2 |
| Oliveira, IB | 2 |
| Heimann, JC | 2 |
| Zhang, Y | 2 |
| Li, B | 1 |
| Wang, B | 2 |
| Morgan, T | 2 |
| Zhao, LM | 1 |
| Wang, LP | 1 |
| Wang, HF | 1 |
| Ma, XZ | 1 |
| Zhou, DX | 1 |
| Deng, XL | 1 |
| Katsuki, M | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Sunagawa, K | 1 |
| Zhao, M | 1 |
| Qin, Y | 1 |
| Lu, L | 1 |
| Tang, X | 1 |
| Wu, W | 1 |
| Fu, H | 1 |
| Liu, X | 2 |
| Bertagnolli, M | 1 |
| Dios, A | 1 |
| Béland-Bonenfant, S | 1 |
| Gascon, G | 1 |
| Sutherland, M | 1 |
| Lukaszewski, MA | 1 |
| Cloutier, A | 1 |
| Paradis, P | 2 |
| Schiffrin, EL | 1 |
| Nuyt, AM | 1 |
| Gao, W | 1 |
| Wang, H | 1 |
| Cao, Y | 1 |
| Bao, JZ | 1 |
| Liu, ZX | 1 |
| Wang, LS | 2 |
| Lu, X | 1 |
| Victorio, JA | 1 |
| Clerici, SP | 1 |
| Palacios, R | 1 |
| Alonso, MJ | 1 |
| Vassallo, DV | 1 |
| Jaffe, IZ | 1 |
| Rossoni, LV | 2 |
| Davel, AP | 1 |
| Koprdova, R | 1 |
| Cebova, M | 1 |
| Kristek, F | 1 |
| Siegl, PK | 1 |
| Kivlighn, SD | 1 |
| Broten, TP | 1 |
| Choi, SM | 1 |
| Seo, MJ | 1 |
| Kang, KK | 1 |
| Kim, JH | 1 |
| Ahn, BO | 1 |
| Yoo, M | 1 |
| Mihailović-Stanojević, N | 1 |
| Miloradović, Z | 1 |
| Grujić-Milanović, J | 1 |
| Ivanov, M | 1 |
| Jovović, D | 1 |
| Zhang, W | 1 |
| Elimban, V | 2 |
| Xu, YJ | 1 |
| Zhang, M | 1 |
| Nijjar, MS | 1 |
| Dhalla, NS | 3 |
| Wachtell, K | 2 |
| Gerdts, E | 2 |
| Aurigemma, GP | 1 |
| Boman, K | 1 |
| Dahlöf, B | 2 |
| Nieminen, MS | 2 |
| Olsen, MH | 1 |
| Okin, PM | 2 |
| Palmieri, V | 1 |
| Rokkedal, JE | 1 |
| Devereux, RB | 2 |
| Zhou, N | 3 |
| Gong, H | 3 |
| Niu, Y | 1 |
| Sun, A | 1 |
| Oikarinen, L | 1 |
| Rakusan, D | 2 |
| Kujal, P | 2 |
| Kramer, HJ | 2 |
| Husková, Z | 2 |
| Vanourková, Z | 2 |
| Vernerová, Z | 2 |
| Mrázová, I | 1 |
| Thumová, M | 1 |
| Cervenka, L | 2 |
| Vanecková, I | 2 |
| Ferreira, DN | 1 |
| Rosa, KT | 2 |
| Coelho, MS | 1 |
| Casarini, DE | 1 |
| Chábová, VČ | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Kopkan, L | 1 |
| Lin, L | 2 |
| Komuro, I | 1 |
| Kalk, P | 1 |
| Sharkovska, Y | 1 |
| Kashina, E | 1 |
| von Websky, K | 1 |
| Relle, K | 1 |
| Pfab, T | 1 |
| Alter, M | 1 |
| Guillaume, P | 1 |
| Provost, D | 1 |
| Hoffmann, K | 1 |
| Fischer, Y | 1 |
| Hocher, B | 2 |
| Do Carmo, EC | 1 |
| Fernandes, T | 1 |
| Koike, D | 1 |
| Da Silva, ND | 1 |
| Mattos, KC | 1 |
| Barretti, D | 1 |
| Melo, SF | 1 |
| Wichi, RB | 1 |
| Irigoyen, MC | 1 |
| de Oliveira, EM | 1 |
| Cingolani, OH | 1 |
| Pérez, NG | 1 |
| Ennis, IL | 2 |
| Alvarez, MC | 1 |
| Mosca, SM | 1 |
| Schinella, GR | 1 |
| Escudero, EM | 1 |
| Cónsole, G | 1 |
| Cingolani, HE | 2 |
| Ye, Y | 1 |
| Wei, J | 1 |
| Liang, Y | 1 |
| Li, Y | 1 |
| Jia, Z | 1 |
| Wu, Y | 1 |
| Zhou, J | 2 |
| Ock, S | 1 |
| Ahn, J | 1 |
| Lee, SH | 1 |
| Park, H | 1 |
| Son, JW | 1 |
| Oh, JG | 1 |
| Yang, DK | 1 |
| Lee, WS | 1 |
| Kim, HS | 1 |
| Rho, J | 1 |
| Oh, GT | 1 |
| Abel, ED | 1 |
| Park, WJ | 1 |
| Min, JK | 1 |
| Kim, J | 1 |
| Campuzano, V | 1 |
| Segura-Puimedon, M | 1 |
| Terrado, V | 1 |
| Sánchez-Rodríguez, C | 1 |
| Coustets, M | 1 |
| Menacho-Márquez, M | 1 |
| Nevado, J | 1 |
| Bustelo, XR | 1 |
| Francke, U | 1 |
| Pérez-Jurado, LA | 1 |
| Babick, A | 1 |
| Chapman, D | 1 |
| Zieroth, S | 1 |
| Itoi, T | 1 |
| Oka, T | 1 |
| Terada, N | 1 |
| Eguchi, K | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Cheng, ZJ | 1 |
| Finckenberg, P | 1 |
| Louhelainen, M | 1 |
| Merasto, S | 1 |
| Vapaatalo, H | 1 |
| Mervaala, EM | 1 |
| Flesch, M | 2 |
| Höper, A | 1 |
| Dell'Italia, L | 1 |
| Evans, K | 1 |
| Bond, R | 1 |
| Peshock, R | 1 |
| Diwan, A | 1 |
| Brinsa, TA | 1 |
| Wei, CC | 1 |
| Sivasubramanian, N | 1 |
| Spinale, FG | 1 |
| Mann, DL | 1 |
| Chamorro, V | 1 |
| Wangensteen, R | 1 |
| Sainz, J | 1 |
| Duarte, J | 1 |
| O'Valle, F | 1 |
| Osuna, A | 1 |
| Vargas, F | 1 |
| Ferron, L | 1 |
| Capuano, V | 1 |
| Ruchon, Y | 1 |
| Deroubaix, E | 1 |
| Coulombe, A | 1 |
| Renaud, JF | 1 |
| Okigaki, M | 1 |
| Iwasaka, T | 1 |
| Ishikawa, Y | 1 |
| Zimmerman, MC | 1 |
| Lazartigues, E | 1 |
| Sharma, RV | 1 |
| Davisson, RL | 1 |
| Shao, Q | 1 |
| Ren, B | 1 |
| Saini, HK | 1 |
| Netticadan, T | 1 |
| Takeda, N | 1 |
| Asai, T | 1 |
| Kushiro, T | 1 |
| Fujita, H | 1 |
| Kanmatsuse, K | 1 |
| Li, T | 1 |
| Sun, S | 1 |
| Xu, F | 1 |
| Jin, X | 1 |
| Xia, L | 1 |
| Shi, JZ | 1 |
| Zheng, Y | 1 |
| Chen, WL | 1 |
| Liu, ZG | 1 |
| Chen, GQ | 1 |
| Fang, NY | 1 |
| Gurusamy, N | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Prakash, P | 1 |
| Hirabayashi, K | 1 |
| Zhang, S | 1 |
| Muslin, AJ | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Sim, MK | 1 |
| Chen, WS | 1 |
| Baumann, M | 1 |
| Janssen, BJ | 1 |
| Hermans, JJ | 1 |
| Peutz-Kootstra, C | 1 |
| Witzke, O | 1 |
| Smits, JF | 1 |
| Struijker Boudier, HA | 1 |
| Fischer, R | 1 |
| Dechend, R | 1 |
| Gapelyuk, A | 1 |
| Shagdarsuren, E | 1 |
| Gruner, K | 1 |
| Gruner, A | 1 |
| Gratze, P | 1 |
| Qadri, F | 1 |
| Wellner, M | 1 |
| Fiebeler, A | 1 |
| Dietz, R | 1 |
| Luft, FC | 1 |
| Muller, DN | 1 |
| Schirdewan, A | 1 |
| Xu, X | 1 |
| Liu, JJ | 1 |
| Lin, YX | 1 |
| Gao, GD | 1 |
| Rocha, FL | 1 |
| Carmo, EC | 1 |
| Roque, FR | 1 |
| Hashimoto, NY | 1 |
| Frimm, C | 1 |
| Anéas, I | 1 |
| Negrão, CE | 1 |
| Krieger, JE | 1 |
| Oliveira, EM | 1 |
| Polizio, AH | 1 |
| Balestrasse, KB | 1 |
| Yannarelli, GG | 1 |
| Noriega, GO | 1 |
| Gorzalczany, S | 1 |
| Taira, C | 1 |
| Tomaro, ML | 1 |
| Zhou, C | 1 |
| Lu, F | 1 |
| Cao, K | 1 |
| Xu, D | 1 |
| Goltzman, D | 1 |
| Miao, D | 1 |
| Liang, B | 1 |
| Leenen, FH | 5 |
| Ishiye, M | 2 |
| Umemura, K | 2 |
| Uematsu, T | 2 |
| Nakashima, M | 2 |
| Mohabir, R | 1 |
| Young, SD | 1 |
| Strosberg, AM | 1 |
| Golomb, E | 1 |
| Abassi, ZA | 1 |
| Cuda, G | 1 |
| Stylianou, M | 1 |
| Panchal, VR | 1 |
| Trachewsky, D | 1 |
| Keiser, HR | 1 |
| O'Sullivan, JB | 1 |
| Black, MJ | 2 |
| Bertram, JF | 1 |
| Bobik, A | 3 |
| Miyata, S | 2 |
| Haneda, T | 2 |
| Rockman, HA | 2 |
| Wachhorst, SP | 1 |
| Mao, L | 2 |
| Ross, J | 1 |
| Ruzicka, M | 3 |
| Yuan, B | 3 |
| Lopez, JJ | 1 |
| Lorell, BH | 1 |
| Ingelfinger, JR | 1 |
| Weinberg, EO | 1 |
| Schunkert, H | 1 |
| Diamant, D | 1 |
| Tang, SS | 1 |
| Kohno, M | 1 |
| Fukui, T | 1 |
| Horio, T | 1 |
| Yokokawa, K | 1 |
| Yasunari, K | 1 |
| Yoshiyama, M | 1 |
| Kurihara, N | 1 |
| Takeda, T | 1 |
| Everett, AD | 1 |
| Tufro-McReddie, A | 1 |
| Fisher, A | 1 |
| Gomez, RA | 1 |
| Timmermans, PB | 1 |
| Wong, PC | 1 |
| Chiu, AT | 1 |
| Herblin, WF | 1 |
| Smith, RD | 1 |
| Ito, H | 1 |
| Hirata, Y | 1 |
| Adachi, S | 1 |
| Tanaka, M | 1 |
| Tsujino, M | 1 |
| Koike, A | 1 |
| Nogami, A | 1 |
| Murumo, F | 1 |
| Hiroe, M | 1 |
| Harmsen, E | 1 |
| Dominiczak, AF | 2 |
| Devlin, AM | 2 |
| Lee, WK | 1 |
| Anderson, NH | 2 |
| Bohr, DF | 1 |
| Reid, JL | 2 |
| Iyer, SN | 1 |
| Katovich, MJ | 1 |
| Osaki, J | 1 |
| Kikuchi, K | 1 |
| Young, MJ | 1 |
| Funder, JW | 1 |
| Kawaguchi, H | 1 |
| Kitabatake, A | 1 |
| Regan, CP | 1 |
| Anderson, PG | 1 |
| Bishop, SP | 1 |
| Berecek, KH | 1 |
| Kobori, H | 1 |
| Ichihara, A | 1 |
| Suzuki, H | 1 |
| Takenaka, T | 1 |
| Miyashita, Y | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Kanellakis, P | 1 |
| Makino, N | 1 |
| Sugano, M | 1 |
| Otsuka, S | 1 |
| Hata, T | 1 |
| Price, RL | 1 |
| Carver, W | 1 |
| Simpson, DG | 1 |
| Fu, L | 1 |
| Zhao, J | 1 |
| Borg, TK | 1 |
| Terracio, L | 1 |
| Zolk, O | 1 |
| Schnabel, P | 1 |
| Teisman, AC | 1 |
| Pinto, YM | 2 |
| van Gilst, WH | 1 |
| Paul, M | 2 |
| Böhm, M | 1 |
| K-Laflamme, A | 1 |
| Oster, L | 1 |
| Cardinal, R | 1 |
| de Champlain, J | 1 |
| Graham, D | 1 |
| Morton, JJ | 1 |
| Hamilton, CA | 1 |
| Schork, NJ | 1 |
| Merlos, M | 1 |
| Rabasseda, X | 1 |
| Silvestre, JS | 1 |
| Wåhlander, H | 1 |
| Wickman, A | 1 |
| Isgaard, J | 1 |
| Friberg, P | 1 |
| Tea, BS | 1 |
| Dam, TV | 1 |
| Moreau, P | 1 |
| Hamet, P | 1 |
| deBlois, D | 1 |
| Bastien, NR | 1 |
| Servant, MJ | 1 |
| Gutkowska, J | 1 |
| Meloche, S | 1 |
| Lambert, C | 1 |
| Richer, C | 1 |
| Gervais, M | 1 |
| Fornes, P | 1 |
| Giudicelli, JF | 1 |
| Butler, KL | 1 |
| Huang, AH | 1 |
| Gwathmey, JK | 1 |
| Magga, J | 1 |
| Kalliovalkama, J | 2 |
| Romppanen, H | 1 |
| Vuolteenaho, O | 1 |
| Pörsti, I | 2 |
| Kähönen, M | 2 |
| Tolvanen, JP | 2 |
| Ruskoaho, H | 1 |
| Dali-Youcef, N | 1 |
| Paradis, FW | 1 |
| Thibault, G | 1 |
| Nemer, M | 1 |
| Kawano, H | 1 |
| Cody, RJ | 1 |
| Graf, K | 1 |
| Goetze, S | 1 |
| Kawano, Y | 1 |
| Schnee, J | 1 |
| Law, RE | 1 |
| Hsueh, WA | 1 |
| Wu, X | 1 |
| Voipio, J | 1 |
| Pekki, A | 1 |
| Doris, PA | 1 |
| Ylitalo, P | 1 |
| Cerbai, E | 1 |
| Crucitti, A | 1 |
| Sartiani, L | 1 |
| De Paoli, P | 1 |
| Pino, R | 1 |
| Rodriguez, ML | 1 |
| Gensini, G | 1 |
| Mugelli, A | 1 |
| Fu, M | 1 |
| Xu, S | 1 |
| Pang, Y | 1 |
| Liu, N | 1 |
| Su, J | 1 |
| Tang, C | 1 |
| Verhagen, AM | 1 |
| Hohbach, J | 1 |
| Joles, JA | 1 |
| Braam, B | 1 |
| Boer, P | 1 |
| Koomans, HA | 1 |
| Gröne, H | 1 |
| Herizi, A | 1 |
| Belabbas, H | 1 |
| Mimran, A | 1 |
| Jover, B | 1 |
| Pinto-Sietsma, SJ | 1 |
| Philipp, T | 1 |
| Engler, S | 1 |
| Kossamehl, P | 1 |
| Marquardt, H | 1 |
| Sethmann, S | 1 |
| Lauster, R | 1 |
| Merker, HJ | 1 |
| Hao, J | 1 |
| Jones, SC | 1 |
| Jassal, DS | 1 |
| Dixon, IM | 1 |
| Knowles, JW | 1 |
| Esposito, G | 1 |
| Hagaman, JR | 1 |
| Fox, JE | 1 |
| Smithies, O | 1 |
| Maeda, N | 1 |
| González Bosc, LV | 1 |
| Kurnjek, ML | 1 |
| Müller, A | 1 |
| Terragno, NA | 1 |
| Basso, N | 1 |
| Sanada, S | 1 |
| Kitakaze, M | 1 |
| Node, K | 1 |
| Takashima, S | 1 |
| Ogai, A | 1 |
| Asanuma, H | 1 |
| Sakata, Y | 1 |
| Asakura, M | 1 |
| Ogita, H | 1 |
| Liao, Y | 1 |
| Fukushima, T | 1 |
| Yamada, J | 1 |
| Minamino, T | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Aubert, JF | 1 |
| Brunner, H | 1 |
| White, R | 1 |
| Takeda, Y | 1 |
| Yoneda, T | 1 |
| Demura, M | 1 |
| Usukura, M | 1 |
| Mabuchi, H | 1 |
| Shimamura, T | 1 |
| Iwasaki, T | 1 |
| Hayasaki-Kajiwara, Y | 1 |
| Naya, N | 1 |
| Nakajima, M | 1 |
| Loennechen, JP | 1 |
| Wisløff, U | 1 |
| Falck, G | 1 |
| Ellingsen, O | 1 |
| Garcia, R | 2 |
| Bonhomme, MC | 1 |
| Diebold, S | 1 |
| Xiu, JC | 1 |
| Wu, P | 1 |
| Xu, JP | 1 |
| Guo, Z | 1 |
| Lai, W | 1 |
| Li, S | 1 |
| Li, J | 1 |
| Wang, Q | 1 |
| Hummler, E | 1 |
| Nussberger, J | 1 |
| Clément, S | 1 |
| Gabbiani, G | 1 |
| Brunner, HR | 1 |
| Burnier, M | 1 |
| Alvarez, BV | 1 |
| De Hurtado, MC | 1 |
| Mizuno, K | 1 |
| Tani, M | 1 |
| Hashimoto, S | 1 |
| Niimura, S | 1 |
| Sanada, H | 1 |
| Watanabe, H | 1 |
| Ohtsuki, M | 1 |
| Fukuchi, S | 1 |
| Oddie, CJ | 1 |
| Dilley, RJ | 1 |
| Qing, G | 1 |
| Dostal, DE | 1 |
| Baker, KM | 1 |
| Linz, W | 1 |
| Henning, R | 1 |
| Schölkens, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study[NCT03255551] | 50 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for losartan and Cardiomegaly
| Article | Year |
|---|---|
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2004 |
[High blood pressure and cardiac hypertrophy].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
New perspectives in angiotensin system control.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; | 1993 |
Discovery of new angiotensin II receptor antagonists. A review of pharmacological studies.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Hu | 1998 |
123 other studies available for losartan and Cardiomegaly
| Article | Year |
|---|---|
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.
Topics: Angiotensin I; Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Hypertension | 2021 |
Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway.
Topics: Angiotensin II; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; | 2023 |
Interleukin enhancement binding factor 3 inhibits cardiac hypertrophy by targeting asymmetric dimethylarginine-nitric oxide.
Topics: Amidohydrolases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arginine; Cardiom | 2019 |
Angiotensin II Increases HMGB1 Expression in the Myocardium Through AT1 and AT2 Receptors When Under Pressure Overload.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Cardiomegaly; Case-Control | 2021 |
Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy.
Topics: Animals; Atrial Natriuretic Factor; Calcineurin; Cardiomegaly; Cell Line; Cyclin-Dependent Kinase In | 2017 |
AT1 receptor blockage impairs NF-κB activation mediated by thyroid hormone in cardiomyocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calgranulin A; Cardiomegaly; Cells, Cultured; Hype | 2018 |
Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Di | 2019 |
Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antimetabolites; Apoptosis; Body Weight; Bromodeox | 2015 |
Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts.
Topics: Angiotensin I; Animals; Cardiomegaly; Imidazoles; In Vitro Techniques; Losartan; Male; NG-Nitroargin | 2013 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Ang II receptor expression and effect of Ang II receptor blockade in thyrotoxic rat myocardium.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Losartan; Male; Myocardium; Peptidyl | 2013 |
Reduced sarcolemmal expression and function of the NBCe1 isoform of the Na⁺-HCO₃⁻ cotransporter in hypertrophied cardiomyocytes of spontaneously hypertensive rats: role of the renin-angiotensin system.
Topics: Ammonium Compounds; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2014 |
AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Heart; KATP Channels; Losartan; Male | 2014 |
Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.
Topics: Angiotensin II; Animals; Cardiomegaly; Chemokine CCL2; Enalaprilat; gamma-Aminobutyric Acid; Glutami | 2014 |
Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Car | 2014 |
Mechanisms involving Ang II and MAPK/ERK1/2 signaling pathways underlie cardiac and renal alterations during chronic undernutrition.
Topics: Adenosine Triphosphatases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood P | 2014 |
High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation.
Topics: Acetylcysteine; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body | 2014 |
Alteration of cardiac ACE2/Mas expression and cardiac remodelling in rats with aortic constriction.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal | 2014 |
The role of KCa3.1 channels in cardiac fibrosis induced by pressure overload in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Aorta, Abdominal; Blood Pressure; | 2015 |
Decreased proportion of Foxp3+ CD4+ regulatory T cells contributes to the development of hypertension in genetically hypertensive rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Forkhead Transcription Factors; Hypertension; Interleukin-2; | 2015 |
[Preliminary Study of Necroptosis in Cardiac Hypertrophy Induced by Pressure Overload].
Topics: Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Echocardiography; Heart; Losartan; Myocyte | 2015 |
Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cardiomegaly; Disease Models, An | 2016 |
Retinol-Binding Protein 4 Induces Cardiomyocyte Hypertrophy by Activating TLR4/MyD88 Pathway.
Topics: Adipocytes; Angiotensin II; Animals; Blotting, Western; Cardiomegaly; Cells, Cultured; Inflammation; | 2016 |
Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.
Topics: Adipose Tissue; Analysis of Variance; Animals; Cardiomegaly; Disease Models, Animal; Isoproterenol; | 2016 |
Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiomeg | 2009 |
Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 1995 |
Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; A | 2009 |
Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Cardiomegaly; | 2009 |
Alterations of cardiac ERK1/2 expression and activity due to volume overload were attenuated by the blockade of RAS.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Calcineurin Inhibitor | 2010 |
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Blood Pressure; Cardiomegaly; Echocardiography; Electrocardiography; Fema | 2010 |
Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.
Topics: Amides; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Mode | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrial Natr | 2010 |
Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Aspartic Acid Endopeptidases; Blood Pressure | 2011 |
Anabolic steroid associated to physical training induces deleterious cardiac effects.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Anabolic Agents; Angiotensin II Type 1 Receptor Blocker | 2011 |
In vivo key role of reactive oxygen species and NHE-1 activation in determining excessive cardiac hypertrophy.
Topics: Animals; Aorta; Cardiomegaly; Ligation; Lipid Peroxidation; Losartan; Male; Mice; Mice, Inbred BALB | 2011 |
Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Cell Proliferation; Disease Models, Animal; Down-Regulati | 2012 |
Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Antibodies, Monoclonal; Antibodi | 2012 |
Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome.
Topics: Acetophenones; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Blood Pre | 2012 |
Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium-Binding Proteins; Cardiomegaly; Catecholam | 2012 |
Modulation of C16:0-ceramide in hypertrophied immature hearts by losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Aortic Valve Stenosis; Cardiomeg | 2013 |
Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).
Topics: Albuminuria; Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood | 2003 |
Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor.
Topics: Age Factors; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Anima | 2003 |
Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cardiomeg | 2004 |
Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Bosentan; Butadienes; C | 2003 |
Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system.
Topics: Adenoviridae; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain Chemistry; Car | 2004 |
Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment.
Topics: Animals; Antihypertensive Agents; Calcium; Calcium-Transporting ATPases; Cardiomegaly; Enalapril; Ge | 2005 |
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Rec | 2005 |
Role of myofibrillogenesis regulator-1 in myocardial hypertrophy.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newb | 2006 |
Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats.
Topics: Age Factors; Aging; Algorithms; Animals; Antihypertensive Agents; Blotting, Western; Cardiomegaly; D | 2006 |
Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol.
Topics: 14-3-3 Proteins; Angiotensin II; Animals; Apoptosis; Blood Glucose; Body Weight; Cardiomegaly; Cardi | 2006 |
Effects of losartan on angiotensin receptors in the hypertrophic rat heart.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequ | 2006 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica | 2007 |
[Blood pressure reduction with additional benefits].
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomegaly; Humans; Hypertension; Losartan | 2007 |
Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; | 2007 |
Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats.
Topics: Anabolic Agents; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension.
Topics: Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Catalase; Glutathione; Hypertension, Renovasc | 2008 |
Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Animals; Antihypertensive Agents; Blood Pressure; Calcium; | 2008 |
Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Benzoates; | 2008 |
Effects of losartan, an angiotensin II antagonist, on the development of cardiac hypertrophy due to volume overload.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cardiac Volume; Cardiomegaly; Imidazole | 1995 |
Angiotensin AT1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Age | 1995 |
Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1994 |
Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats.
Topics: Actins; Angiotensin II; Animals; Base Sequence; Biphenyl Compounds; Blood Pressure; Captopril; Cardi | 1994 |
Cardiovascular hypertrophy in one-kidney, one clip renal hypertensive rats: a role for angiotensin II?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1994 |
Hypertrophic growth of cultured neonatal rat heart cells mediated by type 1 angiotensin II receptor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compounds; Cal | 1994 |
ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Atrial N | 1994 |
Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Volume; Body Weight; Cardiomegaly; Coron | 1994 |
Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding Sites; Biphenyl Compounds; Cardio | 1994 |
Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension.
Topics: Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Cardiom | 1994 |
Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression.
Topics: Angiotensin II; Animals; Aortic Coarctation; Atrial Natriuretic Factor; Biphenyl Compounds; Cardiome | 1994 |
Renin-angiotensin system and minoxidil-induced cardiac hypertrophy in rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Enalapril; Heart; Hemodyn | 1993 |
Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes.
Topics: Angiotensin II; Animals; Base Sequence; Biphenyl Compounds; Cardiomegaly; Cells, Cultured; Endotheli | 1993 |
The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.
Topics: Angiotensin II; Animals; Aorta; Arteriovenous Shunt, Surgical; Biphenyl Compounds; Body Weight; Card | 1993 |
Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl | 1996 |
Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
Renin-angiotensin system in stretch-induced hypertrophy of cultured neonatal rat heart cells.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1996 |
The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis.
Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Body Weight; Canr | 1996 |
Altered signal transduction system in hypertrophied myocardium: angiotensin II stimulates collagen synthesis in hypertrophied hearts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Biphenyl Compounds; Blood Pressure | 1997 |
Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood; Cardiomegaly; Hemodynamics; Hyperthyroi | 1997 |
Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Antihypertensiv | 1997 |
Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Ca | 1997 |
The effects of angiotensin II and specific angiotensin receptor blockers on embryonic cardiac development and looping patterns.
Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cardiomegaly; Fetal Heart; Fibrob | 1997 |
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
Topics: Adenylyl Cyclases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anima | 1998 |
Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Cardiomegaly; Desoxycorticosterone; Endothelium, V | 1998 |
Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Cell Nucleus; Diastole; DNA; | 1999 |
Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Abdominal; Aortic | 1999 |
Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 1999 |
Downregulation of cardiac AT1-receptor expression and angiotensin II concentrations after long-term blockade of the renin-angiotensin system in cardiomyopathic hamsters.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Cardiomegaly; Crice | 1999 |
Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
AT1-receptor blockade enhances ischemic preconditioning in hypertrophied rat myocardium.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Cardiomegaly; Heart; Heart R | 1999 |
Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats.
Topics: Adrenomedullin; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Natriuret | 2000 |
Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
Topics: Actinin; Age Factors; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antigens, CD; Antih | 2000 |
Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes.
Topics: Action Potentials; Angiotensin Receptor Antagonists; Animals; Cardiomegaly; Electric Conductivity; H | 2000 |
Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats.
Topics: Angiotensin II; Animals; Animals, Newborn; Atrial Natriuretic Factor; Calcineurin; Calcineurin Inhib | 1999 |
Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiomegaly; Dose-Respon | 2000 |
[Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan].
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 2000 |
Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Diseases; Heart Ventricles; Hypertens | 2000 |
Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro.
Topics: Active Transport, Cell Nucleus; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihyper | 2000 |
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Enalapril; Furosemide; Guanylate Cyc | 2001 |
Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; A | 2001 |
Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; | 2001 |
Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Cardiomegaly; Circadian | 2001 |
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
Topics: Adrenergic beta-Agonists; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pre | 2001 |
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Bo | 2002 |
Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP.
Topics: Aldosterone; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiomegaly; Circadian | 2002 |
Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure.
Topics: Angiotensins; Animals; Anti-Arrhythmia Agents; Calcium Signaling; Cardiomegaly; Cell Separation; Cel | 2002 |
Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood | 1996 |
Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; | 2002 |
Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes.
Topics: Animals; Blood Pressure; Cardiomegaly; Desoxycorticosterone; Hyperplasia; Kidney; Losartan; Mice; Mi | 2002 |
Effects of antihypertensive therapy on cardiac sodium/hydrogen ion exchanger activity and hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Disease Mo | 2002 |
Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 1992 |
Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardi | 1992 |
Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriure | 1992 |
Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardi | 1992 |
Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1991 |